Rituximab therapy induces long lasting remissions and reduction of anti-platelet glycoprotein autoantibodies in patients with chronic immune thrombocytopenic purpura (ITP) - Ahn, ER; Bidot, C; Fontana, V (Blood, 2005)
[abstract].